Abstract

Super-enhancers regulate genes with important functions in processes that are cell type-specific or define cell identity. Mouse embryonic fibroblasts establish 40 senescence-associated super-enhancers regardless of how they become senescent, with 50 activated genes located in the vicinity of these enhancers. Here we show, through gene knockdown and analysis of three core biological properties of senescent cells that a relatively large number of senescence-associated super-enhancer-regulated genes promote survival of senescent mouse embryonic fibroblasts. Of these, Mdm2, Rnase4, and Ang act by suppressing p53-mediated apoptosis through various mechanisms that are also engaged in response to DNA damage. MDM2 and RNASE4 transcription is also elevated in human senescent fibroblasts to restrain p53 and promote survival. These insights identify key survival mechanisms of senescent cells and provide molecular entry points for the development of targeted therapeutics that eliminate senescent cells at sites of pathology.

To develop therapeutics that selectively eliminate pathological senescent cells it is important to understand their survival mechanisms. Here, the authors show that senescent cells manage to survive by keeping p53 activity in check through multiple mechanisms, including inhibitory mechanisms that involve p53 binding to ribonucleases.

Details

Title
Senescent cells limit p53 activity via multiple mechanisms to remain viable
Author
Sturmlechner, Ines 1   VIAFID ORCID Logo  ; Sine, Chance C. 2 ; Jeganathan, Karthik B. 2 ; Zhang, Cheng 3 ; Fierro Velasco, Raul O. 2   VIAFID ORCID Logo  ; Baker, Darren J. 4   VIAFID ORCID Logo  ; Li, Hu 3   VIAFID ORCID Logo  ; van Deursen, Jan M. 4   VIAFID ORCID Logo 

 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); University of Groningen, University Medical Center Groningen, Department of Pediatrics, Molecular Genetics Section, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598) 
 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Pediatric and Adolescent Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Department of Biochemistry and Molecular Biology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2681634284
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.